Amgen (AMGN) Stock Price vs Revenue
Open the interactive overlay on autario.com.
Amgen's Q1 2026 revenue of $8.6B represents a 5.76% increase compared to Q1 2025's $8.1B. Over that same year, the stock price rose from $311.55 to $351.85, a gain of 12.94%, indicating the valuation expanded relative to revenue growth. The stock has since pulled back to $326.42 as of June 2, 2026. Across the broader 43-year window from June 1983 through June 2026, Amgen's stock price and revenue show a correlation of 0.73, reflecting a historically strong but not perfect alignment between the company's financial performance and equity valuation.
Revenue was $8.6B as of 2026-03-31, +5.8% year over year. The stock moved +13% over the same window ($311.55 -> $351.85). Price and Revenue moved almost in lockstep.
Latest close: 326.62 USD (2026-06-02).
Revenue | recent SEC reports
| Report date | Revenue | Period |
|---|
| 2026-03-31 | 8.6B USD | Q1 10-Q |
| 2025-09-30 | 9.6B USD | Q3 10-Q |
| 2025-06-30 | 9.2B USD | Q2 10-Q |
| 2025-03-31 | 8.1B USD | Q1 10-Q |
| 2024-09-30 | 8.5B USD | Q3 10-Q |
| 2024-06-30 | 8.4B USD | Q2 10-Q |
| 2024-03-31 | 7.4B USD | Q1 10-Q |
| 2023-09-30 | 6.9B USD | Q3 10-Q |
Sources: autario.com/data/stock-amgn-amgen-daily-prices · autario.com/data/amgen-revenue-sec-filings | data verified and hosted on autario.com.